Work

Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.9052

Authors: Arielle Elkrief, Joao Victor Machado Alessi, Biagio Ricciuti, Hira Rizvi, Isabel Ruth Preeshagul, Jacklynn V. Egger, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Matthew D. Hellmann, Mark M. Awad, Adam Jacob Schoenfeld

Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281689654

Cites:

Cited by: 2

Related to: 10